Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Earnings Per Share

v3.22.0.1
Note 9 - Earnings Per Share
6 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 9. Earnings Per Share:

 

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

 

   

Quarter Ended

   

Six Months Ended

 
   

December 31,

   

December 31,

 
   

2021

   

2020

   

2021

   

2020

 

Earnings per share – basic:

                               

Net earnings, including noncontrolling interest

  $ 72,059     $ 46,144     $ 141,040     $ 79,538  

Less net earnings (loss) attributable to noncontrolling interest

    (8,114 )     (130

)

    (8,748 )     (130

)

Net earnings attributable to Bio-Techne

  $ 80,173     $ 46,274     $ 149,788     $ 79,668  

Income allocated to participating securities

    (34 )     (37

)

    (70 )     (50

)

Income available to common shareholders

  $ 80,139     $ 46,237     $ 149,718     $ 79,618  

Weighted-average shares outstanding – basic

    39,310       38,691       39,202       38,614  

Earnings per share – basic

  $ 2.04     $ 1.20     $ 3.82     $ 2.06  
                                 

Earnings per share – diluted:

                               

Net earnings, including noncontrolling interest

  $ 72,059     $ 46,144     $ 141,040     $ 79,538  

Less net earnings (loss) attributable to noncontrolling interest

    (8,114 )     (130

)

    (8,748 )     (130

)

Net earnings attributable to Bio-Techne

  $ 80,173     $ 46,274     $ 149,788     $ 79,668  

Income allocated to participating securities

    (34 )     (37

)

    (70 )     (50

)

Income available to common shareholders

  $ 80,139     $ 46,237     $ 149,718     $ 79,618  

Weighted-average shares outstanding – basic

    39,310       38,691       39,202       38,614  

Dilutive effect of stock options and restricted stock units

    1,897       1,566       1,957       1,521  

Weighted-average common shares outstanding – diluted

    41,207       40,257       41,159       40,135  

Earnings per share – diluted

  $ 1.94     $ 1.15     $ 3.64     $ 1.98  

 

The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.7 million and 1.6 million for the quarter ended December 31, 2021 and 2020, respectively and 0.5 million and 1.5 million for the six months ended December 31, 2021 and 2020 respectively.